Plasma brain natriuretic peptide in obstructive sleep apnea

Area of Science:

• Cardiology
• Sleep Medicine
• Endocrinology

Background:

• Obstructive sleep apnea (OSA) is a common condition linked to cardiovascular issues.
• Natriuretic peptides, including brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP), are important biomarkers in cardiovascular health.

Purpose of the Study:

• To investigate the relationship between obstructive sleep apnea (OSA) and natriuretic peptide levels (BNP and ANP).
• To compare BNP and ANP levels in patients with OSA (with and without cardiovascular disease) versus healthy controls.

Main Methods:

• Blood samples were collected to measure plasma BNP and ANP levels.
• Measurements were taken during wakefulness and overnight in subjects with and without OSA, including those with cardiovascular disease.
• The effect of OSA treatment on ANP levels was also assessed.

Main Results:

• Obstructive sleep apnea (OSA) was not associated with elevated plasma BNP or ANP during wakefulness in healthy individuals.
• Untreated OSA led to a significant increase in ANP levels overnight.
• Treatment of OSA resulted in a decrease in overnight ANP levels.
• OSA did not cause acute overnight changes in BNP, irrespective of the presence of cardiovascular disease or chronic heart failure.

Conclusions:

• Obstructive sleep apnea (OSA) does not acutely impact brain natriuretic peptide (BNP) levels, even in patients with cardiovascular disease.
• Atrial natriuretic peptide (ANP) is sensitive to acute changes caused by untreated OSA overnight, with levels normalizing upon treatment.